Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions
Executive Summary
Anticipating annual pricing of up to $10,000 per patient for PCSK9 cholesterol-lowering drugs that will be prescribed for life, payers are taking a very close look at how to limit use to the patients who most need to take the drugs in the new class instead of low-cost statins.
You may also be interested in...
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press
Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.